Kaitlyn Kosko

DocwireNews

Patients with lung adenocarcinomas who have high TMB likely will not benefit from adjuvant chemotherapy, according to Prashanth Ashok Kumar, MD, and colleagues. Their findings were published in Clinical Lung Cancer.Using the LACE Bio II database, the researchers identified 375 patients who were then divided according to adenocarcinoma subtype. The following subtypes were included in the analysis: lepidic, acinar/papillary, micropapillary/solid (MIP/SOL), mucinous (MUC), and others. Study end points included OS, DFS, and lung cancer-specific survival (LCSS). The survival outcomes were compared using the Kaplan-Meier method and log-rank test based on PD-L1, TMB, and tumor-infiltrating lymphocytes (TILs).MIP/SOL was the subtype most commonly positive for different biomarkers. In addition, patients who were PD-L1 negative with high TMB had better OS and DFS outcomes relative to those who were PD-L1 negative with low TMB.Regarding adjuvant chemotherapy, those with high TMB were predicted to have worse OS outcomes.&ldquo;The high TMB group had a poor outcome with [adjuvant chemotherapy], suggesting that this group may be better served with immune checkpoint therapy,&rdquo; the authors wrote.Adjuvant chemotherapy showed a survival benefit in patients with marked TILs, who had better outcomes for DFS and LCSS. DFS was also positively associated with patients with marked TILs and low TMB.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Tumor Mutation Burden Might Predict Who Is Suited for Adjuvant Chemotherapy

Lung Cancer

Patients with lung adenocarcinomas who have high TMB likely will not benefit from adjuvant chemotherapy.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe